Patritumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Patritumab
Monoclonal antibody
Type Whole antibody
Source Human
Target HER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none

Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.[1]

Clinical trials[edit]

It is in a phase 2 clinical trial for squamous cell cancer of the head and neck.[2]

It is to be included in a new arm of the I-SPY 2 breast cancer trial.[3]

References[edit]

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4). 
  2. ^ A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck
  3. ^ Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer. Oct 2016